Candice Bohn currently serves as a Principal Investigator at Sanofi Pasteur, where she plays a pivotal role in advancing vaccine development through her expertise in antigen deviation investigation. With a robust background in the pharmaceuticals industry, Candice leverages her extensive skills in cGMP practices and...
Candice Bohn currently serves as a Principal Investigator at Sanofi Pasteur, where she plays a pivotal role in advancing vaccine development through her expertise in antigen deviation investigation. With a robust background in the pharmaceuticals industry, Candice leverages her extensive skills in cGMP practices and technical writing to ensure compliance and enhance the quality of training programs. Her experience as a Training Coordinator has equipped her with a unique perspective on the importance of effective training and onboarding processes, particularly in the context of complex pharmaceutical environments.
In her current role, Candice is deeply involved in key projects that focus on understanding and mitigating antigen deviation, a critical aspect of vaccine efficacy and safety. Her work not only contributes to the scientific community but also aligns with Sanofi Pasteur's commitment to delivering high-quality vaccines to protect public health. Candice's proficiency in meeting facilitation and curriculum evaluation ensures that her team remains aligned and informed, fostering an environment of continuous learning and improvement.
Candice's educational background, with a Master of Science in Occupational Therapy from Misericordia University, enhances her ability to approach challenges from a holistic perspective, particularly in pediatric applications. Her strong foundation in quality systems and human resources further supports her initiatives in training coordination and production support, making her an invaluable asset to Sanofi Pasteur. Through her dedication to troubleshooting and enhancing training methodologies, Candice continues to drive innovation and excellence within the pharmaceutical sector, ultimately contributing to the development of safer and more effective vaccines for children and adults alike.